Ensysce says Taiwan grants MPAR overdose-protection patent through 2042
PUBT · 05/12 12:01
Share
Listen to the news
- Ensysce Biosciences secured a Taiwan patent covering MPAR overdose-protection technology, extending jurisdictional protection through 2042.
- Patent includes composition-of-matter claims, method-of-use claims tied to enzyme-cleavable prodrugs, controlled-release nafamostat.
- Coverage expands U.S. Patent No. 12,599,578, issued April 14, 2026.
- MPAR holds FDA Breakthrough Therapy designation, aims to curb opioid release in overdose scenarios while maintaining pain relief when used as directed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605120800ACCESSWRNAPR_____1165814) on May 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved